Stay updated on Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial page.

Latest updates to the Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page now shows Revision: v3.4.2, and the previous government funding notice (the lapse notice with related guidance) has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check21 days agoChange DetectedIntroduced a site-wide notice regarding a lapse in government funding and updated operating status information for the NIH Clinical Center. The page footer revision changed from v3.4.0 to v3.4.1.SummaryDifference0.3%

- Check28 days agoChange DetectedUI updates include adding a glossary display and updating last-update fields (Last Update Submitted that Met QC Criteria, Last Update Posted) along with the page revision to v3.4.0. The previous v3.3.4 revision and the (Estimated) Last Update Posted tag were removed, and No FEAR Act data labeling was adjusted.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page indicates a minor version update from v3.3.3 to v3.3.4 with no apparent changes to study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedThe Contacts and Locations section was updated to add multiple new sites across the US (including California, Colorado, Connecticut, Florida, Illinois, Indiana, Kansas, Maryland, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New York, Ohio, Oregon, Pennsylvania, Utah) and a location in Vienne, while removing several existing entries; this reflects updated site availability and contact points for potential participants.SummaryDifference1%

- Check92 days agoChange DetectedPubMed publications note updated to indicate automatic filling from PubMed and Revision: v3.3.2; the previous PubMed note and Revision: v3.2.0 were removed.SummaryDifference0.1%

Stay in the know with updates to Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial page.